Sevelamer Carbonate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

碳酸司维拉姆是一种非吸收性磷酸盐结合交联聚合物，具有与盐酸司维拉姆相同的聚合结构，其中碳酸根取代氯离子作为抗衡离子。

Sevelamer carbonate is a non-absorbed phosphate binding crosslinked polymer, with the same polymeric structure as sevelamer hydrochloride, in which carbonate replaces chloride as the counterion.

Sevelamer carbonate (15 mg/mL; pH=6 or 8) decreases serum levels of gut-derived uremic toxins (such as IAA) or limits the elevation of gut-derived uremic toxins (initial concentration=1 μg/mL or 10 μg/mL).

Sevelamer carbonate is an anion-exchange resin with the same polymeric structure as that of sevelamer hydrochloride, but with carbonate replacing chloride as the anion.Sevelamer carbonate lowers serum phosphorus levels and calcium-phosphorus product to a similar extent as sevelamer hydrochloride. Additionally, Sevelamer carbonate is associated with significant effects on decreasing low-density lipoprotein cholesterol levels and may cause less metabolic acidosis than sevelamer hydrochloride in vivo.Sevelamer carbonate (oral adminstration; 1% mixed in diet; 2-3 weeks) significantly reduces serum phosphate level in Npt2b-deficient mice. Npt2b attenuates the hyperphosphatemia in control animals and that sevelamer carbonate treatment has an additional benefit in maintaining serum phosphate in the normal range.Sevelamer carbonate (oral adminstration; ? 1% mixed in diet; 2-3 weeks) does not alter serum phosphate levels in uremic WT mice (10.04 mg/dl , untreated versus 9.67mg/dl , binder-treated mg/dl) but further decreased serum phosphate levels in uremic Npt2b?/??mice in uremic mouse model. Animal Model:WT and Npt2b?/??CKD mice model Dosage:1% mixed in diet Administration:Oral adminstration; 1% mixed in diet; 2-3 weeks Result:Attenuated chronic hyperphosphatemia in mice.

——

Others

Other Targets

Others

——

——

845273-93-0

——

(C3H7N·C3H5ClO)x·xCH2O3

>98% (HPLC)

——

C=CCN.C1C(O1)CCl.C(=O)(O)O

——

(-20℃)

With Ice Pack

≥ 2 years